Source:http://linkedlifedata.com/resource/pubmed/id/15541400
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2004-11-15
|
pubmed:abstractText |
3-Deoxyglucosone (3-DG) is a metabolite of glucose that is thought to lead to the production of advanced glycation end products in diabetes. The previous assay for 3-DG in serum was based on a multi-step protocol, including derivatization, extraction, HPLC separation, and detection. In the current studies, we established a monoclonal antibody that recognizes the 3-DG-derivative, which is generated by the reaction of 3-DG and a 2,3-diamino-benzene derivative. Attachment of a biotin moiety to the 2,3-diamino-benzene ring via a linker allowed development of a highly sensitive chemiluminescent enzyme immunoassay for 3-DG equivalents. Unlike the previous assay, this method does not require extraction of 3-DG derivatives from serum. Treatment of 3-DG in serum with the DAB-link-biotin produced a quinoxaline derivative, which was specifically recognized by the monoclonal antibody. Using this assay, we found that serum 3-DG was higher in streptozotocin-induced diabetic rats than in normal control rats (25+/-5.6 vs. 9.8+/-1.1 microg/L). This simple assay may allow the monitoring of conditions leading to the accumulation of advanced glycation end products and evaluation of the risk of complications in diabetic patients.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/3-deoxyglucosone,
http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers,
http://linkedlifedata.com/resource/pubmed/chemical/Deoxyglucose,
http://linkedlifedata.com/resource/pubmed/chemical/Glycosylation End Products, Advanced,
http://linkedlifedata.com/resource/pubmed/chemical/Streptozocin
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0006-291X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
17
|
pubmed:volume |
325
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1090-8
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:15541400-Animals,
pubmed-meshheading:15541400-Biological Markers,
pubmed-meshheading:15541400-Blood Chemical Analysis,
pubmed-meshheading:15541400-Deoxyglucose,
pubmed-meshheading:15541400-Diabetes Mellitus, Experimental,
pubmed-meshheading:15541400-Glycosylation End Products, Advanced,
pubmed-meshheading:15541400-Immunoenzyme Techniques,
pubmed-meshheading:15541400-Male,
pubmed-meshheading:15541400-Rats,
pubmed-meshheading:15541400-Rats, Sprague-Dawley,
pubmed-meshheading:15541400-Reproducibility of Results,
pubmed-meshheading:15541400-Sensitivity and Specificity,
pubmed-meshheading:15541400-Streptozocin
|
pubmed:year |
2004
|
pubmed:articleTitle |
Immunochemical detection of 3-deoxyglucosone in serum.
|
pubmed:affiliation |
Fujirebio Inc., Research and Development Division, 51 Komiya-cho, Hachioji, Tokyo 192-0031, Japan. yk-uchida@fujirebio.co.jp
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Evaluation Studies,
Validation Studies
|